In recent years, the treatment landscape for hematologic malignancies has gradually shifted from simple “disease control” toward an era of “long-term chronic disease management.” Especially for diseases such as myelofibrosis (MF), which often require prolonged or even lifelong treatment, patients are not only concerned about therapeutic efficacy, but also increasingly value long-term treatment convenience, medication adherence, and quality of life.

Recently, the U.S. Food and Drug Administration (FDA) officially approved the extended-release formulation of ruxolitinib (Ruxolitinib), Jakafi XR, for the treatment of specific myeloproliferative neoplasms (MPNs) and graft-versus-host disease (GVHD). Compared with the traditional twice-daily regimen, the new formulation enables once-daily dosing, drawing significant attention across the hematologic oncology field.

This approval not only represents an important advancement in ruxolitinib formulation optimization, but also highlights how the global innovative drug industry is accelerating into the “long-acting era.”

 

Why Does Myelofibrosis Require Long-Term Treatment?

Myelofibrosis is a rare chronic myeloproliferative disorder characterized by the formation of excessive fibrous tissue within the bone marrow, which disrupts normal blood cell production. As the disease progresses, patients may develop anemia, splenomegaly, fatigue, night sweats, weight loss, and bone pain.

Because the disease is often difficult to cure completely, most patients require long-term pharmacologic management. Currently, abnormal activation of the JAK-STAT signaling pathway is considered one of the major mechanisms driving myelofibrosis progression. As the world’s first approved JAK1/JAK2 inhibitor, ruxolitinib has become a cornerstone therapy in the treatment of myelofibrosis since its initial approval in 2011.

Its primary therapeutic effects include:

●  Reducing splenomegaly

●  Improving systemic symptoms

●  Regulating inflammatory cytokine levels

●  Enhancing patients’ quality of life

As more patients enter long-term treatment phases, optimizing dosing regimens has become an increasingly important focus for the industry.

 

Why Is “Once-Daily Dosing” So Important?

For patients with chronic diseases, long-term medication adherence often directly affects treatment outcomes. Conventional immediate-release ruxolitinib tablets generally require twice-daily administration, and frequent dosing over extended periods may lead to missed doses, medication fatigue, and administration errors.

This challenge is particularly significant among elderly patients and individuals receiving multiple concomitant therapies, where complex treatment schedules can substantially increase management burdens. Research suggests that reduced long-term adherence may result in:

●  Unstable disease control

●  Increased symptom fluctuations

●  Higher healthcare costs

●  Greater hospitalization risk

As a result, the global pharmaceutical industry has increasingly emphasized long-acting and extended-release drug development. One of the key objectives of the newly approved Jakafi XR extended-release tablets is to reduce dosing frequency and improve long-term treatment convenience.

 

What Improvements Does Jakafi XR Offer?

The FDA approval was primarily based on a pivotal bioequivalence study (NCT06555081). Results demonstrated that the extended-release tablets achieved equivalent total drug exposure compared with the conventional formulation, while also exhibiting smoother pharmacokinetic characteristics.

Comparison Item	Conventional Tablets	Jakafi XR Extended-Release Tablets
Dosing Frequency	Twice daily	Once daily
Time to Peak Concentration (Tmax)	2 hours	3 hours
Half-life	3 hours	5.4 hours
Plasma Concentration Fluctuation	More pronounced	More stable
Peak Concentration (Cmax)	Higher	Reduced by ~25%

Compared with conventional tablets, the most notable advantage of the extended-release formulation is its ability to release the drug more steadily within the body. This design may help:

●  Extend drug activity duration

●  Reduce plasma concentration fluctuations

●  Lower peak-to-trough variability

●  Improve long-term treatment stability

For patients requiring chronic treatment for myelofibrosis, a more stable drug-release profile may offer substantial clinical benefits.

 

Why Has Long-Acting Drug Development Become a Major Trend?

In the past, pharmaceutical development often focused primarily on short-term efficacy. Today, as chronic disease management concepts continue to evolve, the industry is increasingly emphasizing whether patients can maintain therapy consistently over the long term.

This trend is especially evident in oncology and hematology, where many patients require continuous treatment for years. As a result, treatment convenience has become an important competitive factor in innovative drug development.

In recent years, technologies such as:

●  Extended-release tablets

●  Long-acting injectables

●  Microsphere formulations

●  Auto-injector systems

have all experienced rapid development.

The core objective of these technologies is to improve the long-term treatment experience through optimized drug delivery systems. Industry experts generally believe that future competition among innovative therapies will depend not only on efficacy, but also on:

●  Long-acting capability

●  Dosing convenience

●  Patient adherence

●  Chronic disease management potential

The approval of Jakafi XR further reflects this growing global trend.

 

What About Safety?

For patients undergoing long-term treatment, safety remains critically important. Current data indicate that Jakafi XR generally maintains the known safety profile of ruxolitinib without identifying new safety concerns.

Known adverse reactions that still require monitoring include:

●  Thrombocytopenia

●  Anemia

●  Leukopenia

●  Increased infection risk

In addition, as with other JAK inhibitors, clinicians should continue monitoring for potential cardiovascular events, thrombotic risks, and secondary malignancies.

Patients receiving long-term therapy should therefore continue regular clinical monitoring. It is also important to note that the extended-release tablets must be swallowed whole and should not be split, crushed, or chewed.

 

Hematologic Cancer Treatment Is Entering the “Long-Term Management Era”

As innovative therapies continue to evolve, more hematologic diseases are gradually transitioning toward chronic disease-style management. This means that future treatment goals will extend beyond simply prolonging survival and increasingly focus on:

●  Improving quality of life

●  Reducing long-term treatment burden

●  Optimizing patient experience

●  Enhancing long-term adherence

From extended-release tablets to advanced long-acting delivery systems, the global pharmaceutical industry is continuously driving treatment model innovation. As more long-acting drug delivery technologies emerge, patients with chronic hematologic disorders such as myelofibrosis may gain access to more stable, convenient, and personalized therapeutic experiences.

 

Conclusion

The FDA approval of Jakafi XR extended-release tablets marks the beginning of a new “long-acting” phase in the long-term treatment of myelofibrosis.

Compared with traditional twice-daily regimens, the once-daily extended-release formulation may not only improve treatment convenience, but also further enhance long-term adherence and quality of life for patients.

As long-acting, extended-release, and precision drug delivery technologies continue to advance, hematologic cancer treatment may truly enter a new era characterized by greater efficiency, stability, and long-term disease management. Hong Kong Dengyue Pharma leverages its global pharmaceutical supply chain to continuously identify high-quality long-acting therapies in hematologic oncology, supporting patient access to advanced formulations through compliant channels and helping safeguard long-term treatment outcomes.